Virtu KCG Holdings LLC Has $300,000 Position in TG Therapeutics, Inc. (TGTX)

Virtu KCG Holdings LLC lessened its stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 65.3% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 29,815 shares of the biopharmaceutical company’s stock after selling 56,001 shares during the quarter. Virtu KCG Holdings LLC’s holdings in TG Therapeutics were worth $300,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in TGTX. Legal & General Group Plc grew its holdings in TG Therapeutics by 4.1% during the 1st quarter. Legal & General Group Plc now owns 9,801 shares of the biopharmaceutical company’s stock valued at $113,000 after buying an additional 384 shares during the last quarter. Hollencrest Securities LLC acquired a new stake in TG Therapeutics during the 2nd quarter valued at $121,000. Fox Run Management L.L.C. acquired a new stake in TG Therapeutics during the 2nd quarter valued at $156,000. Bank of America Corp DE grew its holdings in TG Therapeutics by 11.0% during the 1st quarter. Bank of America Corp DE now owns 14,076 shares of the biopharmaceutical company’s stock valued at $164,000 after buying an additional 1,395 shares during the last quarter. Finally, HighTower Advisors LLC acquired a new stake in TG Therapeutics during the 1st quarter valued at $170,000. Hedge funds and other institutional investors own 49.86% of the company’s stock.

TG Therapeutics, Inc. (TGTX) opened at 8.15 on Friday. The stock’s market capitalization is $507.83 million. TG Therapeutics, Inc. has a 12 month low of $4.10 and a 12 month high of $15.35. The company has a 50 day moving average price of $10.82 and a 200 day moving average price of $11.14.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.45) EPS for the quarter, beating the consensus estimate of ($0.46) by $0.01. TG Therapeutics had a negative net margin of 68,806.59% and a negative return on equity of 154.02%. The business had revenue of $0.04 million for the quarter, compared to analysts’ expectations of $0.04 million. Equities research analysts predict that TG Therapeutics, Inc. will post ($1.84) earnings per share for the current year.

A number of research analysts have weighed in on the company. BidaskClub lowered TG Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Thursday, July 6th. Zacks Investment Research raised TG Therapeutics from a “hold” rating to a “buy” rating and set a $12.00 price target on the stock in a research note on Thursday, July 13th. ValuEngine lowered TG Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, October 16th. Finally, SunTrust Banks, Inc. reissued a “buy” rating and set a $28.00 price target on shares of TG Therapeutics in a research note on Tuesday, October 3rd. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and nine have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $25.11.

ILLEGAL ACTIVITY WARNING: “Virtu KCG Holdings LLC Has $300,000 Position in TG Therapeutics, Inc. (TGTX)” was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another domain, it was stolen and reposted in violation of US & international copyright and trademark law. The legal version of this story can be read at https://www.dispatchtribunal.com/2017/10/29/tg-therapeutics-inc-tgtx-shares-sold-by-virtu-kcg-holdings-llc.html.

About TG Therapeutics

TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.

Institutional Ownership by Quarter for TG Therapeutics (NASDAQ:TGTX)

Receive News & Ratings for TG Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply